Menu
Recruiting NCT05839392

Novel Approaches to Target MECOM/EVI1 in AML

No phase Interventional AML, Adult

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Biological characterization of AML with MECOM or atypical 3q26 rearrangements.
Who it may be relevant to
Registry conditions: AML, Adult. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Novel Approaches to Target MECOM/EVI1 in Acute Myeloid Leukemia

Overview

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.

Detailed description

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements. To this end, BM samples and formalin fixed/paraffin-embedded BM biopsies will be collected at enrolment, before and after treatment, at relapse.

Interventions

  • Biological Biological characterization of AML with MECOM or atypical 3q26 rearrangements
    Peripheral blood and bone marrow withdrawal

Primary outcome measures

  • Identification of MECOM/EVI1 regulators or downstream effectors potentially druggable [Time frame: At baseline]

Eligibility criteria

Inclusion criteria

  • AML with MECOM or atypical 3q26 rearrangements.
  • Age ≥18.
  • Signed written informed consent according to ICH/EU/GCP and national local laws.

Exclusion criteria

  • None

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

Italy · 1 center
  • Ematologia — Piacenza

Identifiers

NCT: NCT05839392 · AML2623

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗